Management of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

August 13th 2021

X. Long Zheng, MD, PhD, gives an overview of acquired thrombotic thrombocytopenic purpura and the treatment considerations for the disease.

AJMC Insights: Lupus Nephritis

August 5th 2021

Rheumatologist Ellen Ginzler, MD, MPH, and nephrologist German Hernandez, MD, FASN, FACP, explore the current treatment landscape of lupus nephritis and the managed care considerations of recent FDA approved therapies for the disease.

Heart Failure With Preserved Ejection Fraction: Current Status and Future Opportunities

January 26th 2021

Key opinion leaders discuss the key differences and unmet needs in disease management for heart failure with preserved ejection fraction and heart failure with reduction ejection fraction.

CAR T-Cell Therapy for the Management of Multiple Myeloma

January 25th 2021

Oncologists explore the opportunity of CAR T-cell therapy for the treatment of relapsed/refractory multiple myeloma.

New Directions in Chemotherapy-Induced Neutropenia

January 18th 2021

A clinician and payer discuss the impact of chemotherapy-induced neutropenia on patients as well as the healthcare system, and discuss the latest in prophylactic treatment, especially during the COVID-19 pandemic.

Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer

January 14th 2021

Examining current treatment options for brain metastases in metastatic HER2+ breast cancer and assessing the clinical and economic burden.

Challenges and Opportunities for Patients With HIV During COVID-19

December 4th 2020

The impact of the COVID-19 pandemic on managing HIV and strategies implemented to address challenges faced by providers.

Current and Future Treatments for the Management of Myelodysplastic Syndrome

August 13th 2020

Employer Opportunities With Biosimilars

August 11th 2020

Understanding the Subpopulations of Pulmonary Hypertension

April 15th 2020